More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-UT-1B: Human Uterine Leiomyosarcoma Cell Line



SK-UT-1B is a subline of the SK-UT-1 human uterine leiomyosarcoma cell line and grows in adherent culture. Although the SK-UT-1B cell line forms tumors when inoculated in immunocompromised mice, the resulting tumors are different from tumors produced by the parental SK-UT-1 cell line. This cell line displays relatively low chromosome instability, compared to other established cancer cell lines.  SK-UT-1B maintains a near-diploid karyotype and is characterized by a very low percentage of polyploid cells. The SK-UT-1B cells have high levels of phosphorylated retinoblastoma protein, compared to the parental SK-UT-1 cells.


This is a subline of the SK-UT-1 cell line.  The parental cell line was established in 1972 from a 75-year-old Caucasian female with a uterine mixed mesodermal tumor consistent with leiomyosarcoma  grade III.


  • Lloyd J. Old, MD, former  William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
  • Germaine Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  •   Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
  •  Chen TR (1988) SK-UT-1B, a human tumorigenic diploid cell line. Cancer Genetics and Cytogenetics 33: 77-81 (PubMed ID: 3383166)
  •    Mao X et al. (2008) Subtle genomic alterations and genomic instability revealed in diploid cancer cell lines. Cancer Letters 267: 49-54 (PubMed ID: 18407410)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

  • For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078,
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354,

Stage of Development

Ready to use